Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : AMXI-5001
CAS No.: 2170491-77-5
Catalog No.: PC-72149Not For Human Use, Lab Use Only.
AMXI-5001 (AMXI 5001) is a novel, highly potent, orally active dual PARP1/2 (IC50 5/0.05 nM) and microtubule polymerization inhibitor, inhibits intracellular PAR formation with IC50 of 7 nM.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $298 | In stock | |
| 10 mg | $458 | In stock | |
| 25 mg | Get quote | ||
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
AMXI-5001 (AMXI 5001) is a novel, highly potent, orally active dual PARP1/2 (IC50 5/0.05 nM) and microtubule polymerization inhibitor, inhibits intracellular PAR formation with IC50 of 7 nM.
AMXI-5001 binds to the catalytic domain of human PARP1 and is a weak tankyrase inhibitor (800-fold lower than IC50 towards either PARP1 or PARP2 enzymes).
AMXI-5001 inhibited tubulin polymerization in a dose-dependent manner.
AMXI-5001 exhibited selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors.
AMXI-5001 is highly active in both BRCA mutated and wild type cancers.
AMXI-5001 elicited a remarkable In vivo preclinical anti-tumor activity in a BRCA mutated TNBC model induced complete regression of established tumors, including exceedingly large tumors, demonstrated superior anti-tumor effects compared to either single agent (PARP or microtubule) inhibitor or combination with both agents.
| M.Wt | 457.465 | |
| Formula | C25H20FN5O3 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
Carbamic acid, N-[6-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]-1H-benzimidazol-2-yl]-, ethyl ester |
|
1. Hassan Lemjabbar-Alaoui, et al. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
